TrialFinder  /  Landscape Report ALZHEIMER DISEASE  ·  2026-10-26 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-10-26
VERSION  v1
SAMPLE  100 of 2527 studies

alzheimer disease

The alzheimer disease clinical trial landscape includes 2527 actively recruiting trials. Semantic expansion identified 1820 additional trials beyond exact-match search, representing a 257.4% discovery lift across related conditions and therapeutic approaches.

Recruiting
2527
active trials
Expansion Lift
+257.4%
1820 additional trials
Top Sponsor
AstraZeneca
2 trials
Dominant Phase
NA
38 of 104 sampled
Pipeline Overview
Phase Distribution
NA
38
Early I
1
Phase 1
8
Phase 2
13
Phase 3
3
Phase 4
3
Other
38
Therapeutic Modalities
OTHER
39
DRUG
30
DEVICE
22
BEHAVIORAL
19
DIAGNOSTIC_TEST
11
DIETARY_SUPPLEMENT
6
BIOLOGICAL
4
PROCEDURE
3
Recruiting vs. Completed (2yr)
Recruiting
2527
Completed
1167
Competitive Landscape
Sponsor Classification
25%
69%
6%
INDUSTRY (4)
OTHER (11)
NIH (1)
Top Sponsors
SponsorTrialsClass
AstraZeneca2INDUSTRY
Massachusetts General Hospital1OTHER
Biogen1INDUSTRY
National Institute of Mental Health (NIMH)1NIH
Cognixion1INDUSTRY
Nader Pouratian1OTHER
Xiangya Hospital of Central South University1OTHER
Chulalongkorn University1OTHER
Queen's University, Belfast1OTHER
Yale University1OTHER
National Yang Ming Chiao Tung University1OTHER
McGill University1OTHER
Barbara Ann Karmanos Cancer Institute1OTHER
Medipol University1OTHER
Pusan National University Yangsan Hospital1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
Florida28Miami
Texas15Houston
California13Irvine
New York10New York
Illinois9Chicago
Massachusetts7Boston
Maryland7Baltimore
Michigan6Farmington Hills
Tennessee6Knoxville
North Carolina5Chapel Hill
Colorado5Aurora
Minnesota4Minneapolis
Ohio4Columbus
Pennsylvania4Philadelphia
Virginia3Norfolk
Georgia3Decatur
Missouri3St Louis
Washington3Kirkland
Indiana2Fort Wayne
Utah2Provo
Expansion Intelligence
+257.4%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
3
Exact
2
Parent
3
Related
4
Therapeutic
Top Expansion Terms
  • neurodegenerative disease Parent
  • dementia Parent
  • amyloid Related
  • tau protein Related
  • mild cognitive impairment Related
  • anti-amyloid antibody Therapeutic
  • lecanemab Therapeutic
  • donanemab Therapeutic
  • tau immunotherapy Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for alzheimer disease
high
Standard searches miss 257% of relevant trials for alzheimer disease — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
1820 additional trials found via expansion vs 707 exact matches
high
Phase 2 volume (13) significantly exceeds Phase 3 (3), indicating a pipeline bottleneck — most candidates are 2-4 years from potential approval.
Phase 2/Phase 3 ratio: 4.3x
medium
3 industry sponsors are actively competing in this space, signaling strong commercial interest and investment validation.
Top industry: AstraZeneca, Biogen, Cognixion
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for alzheimer disease and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
NCT05336695 PHASE1, PHASE2
Assess Fibrin in Brains With AD/ADRD
Massachusetts General Hospital n=30 Massachusetts General Hospital Boston, Massachusetts
Intervention DIAGNOSTIC_TEST: PET/MR Imaging — PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
Eligibility Ages 55 Years – 90 Years
Contact Ciprian Catana, MD, PhD · 617-643-4885 · ccatana@mgh.harvard.edu
NCT07221669 PHASE3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Biogen n=30 Ann and Robert H Lurie Childrens Hospital of Chicago Chicago, Illinois
Intervention DRUG: Salanersen — Administered intrathecally
Eligibility Ages 0 Days – 42 Days
Contact US Biogen Clinical Trial Center · 866-633-4636 · clinicaltrials@biogen.com
NCT04396873 PHASE1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
National Institute of Mental Health (NIMH) n=184 National Institutes of Health Clinical Center Bethesda, Maryland
Intervention DRUG: 11C-MC1 — Injected IV followed by PET scanning
Eligibility Ages 18 Years – 99 Years
Contact Tara N Turon, C.R.N.P. · (301) 827-6599 · tara.turon@nih.gov
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
Cognixion n=10 Cognixion Santa Barbara, California
Intervention DEVICE: Cognixion ONE — A wearable augmented reality brain computer interface with self contained computer and software to enable communication ...
Eligibility Ages 18 Years
Contact Christopher Principal Investigator · 8053200774 · chris@cognixion.com
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
Nader Pouratian n=2 UT Southwestern Medical Center Dallas, Texas
Intervention DEVICE: Mind Extender (MindEx) — NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is prima...
Eligibility Ages 18 Years – 65 Years
Contact Olivia Gibble, MS · 214-648-8880 · Olivia.gibble@utsouthwestern.edu
Chinese DENOVO PD Registry
Xiangya Hospital of Central South University n=300 Xiangya Hospital of Central South University Changsha, Hunan
Eligibility Ages 30 Years – 75 Years
Contact Jifeng Guo, Ph.D · +8613974936815 · guojifeng2003@163.com
Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease
Chulalongkorn University n=100 King Chulalongkorn Memorial hospital, The Thai Red Cross Society Bangkok, Pathumwan
Intervention DEVICE: Personalized rTMS — Personalized repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
Eligibility Ages 18 Years – 80 Years
Contact Jakkrit Amornvit, MD · Thailand: 88-951-9195 · jakkrit.a@chula.ac.th
MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease
Queen's University, Belfast n=120 Remote assessments from Centre for Public Health, Queens University Belfast Belfast
Intervention BEHAVIORAL: MediPD Online Mediterranean Diet Program — MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provide...
Eligibility Ages 18 Years
Contact Nicola A Ward, PhD, MSci · +44(0)7823368444 · medipd@qub.ac.uk
NCT05586581 PHASE1, PHASE2
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Yale University n=70 Yale School of Medicne, Neuro ID Research Program New Haven, Connecticut
Intervention DRUG: SV2A PET — SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
Eligibility Ages 18 Years – 80 Years
Contact Allison Nelson, RN · (475) 434-4324 · allison.nelson@yale.edu
The Effects of fNIRS-based Neurofeedback Training on Balance and Gait in Parkinson's Disease
National Yang Ming Chiao Tung University n=93 National Yang Ming Chiao Tung University Taipei, None Selected
Intervention OTHER: fNIRS-based neurofeedback with motor imagery — A multichannel wearable fNIRS (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NY, USA) will be used to detect the ...
Eligibility Ages 40 Years – 85 Years
Contact Ray-Yau Wang · +88628267210 · rywang@nycu.edu.tw
Comprehensive Assessment of Neurodegeneration and Dementia
McGill University n=1573 University of Calgary Calgary, Alberta
Eligibility Ages 50 Years – 90 Years
Contact Howard Chertkow, MD · 514 340 8222 · howard.chertkow@mcgill.ca
NCT06420167 PHASE2
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Barbara Ann Karmanos Cancer Institute n=20 Karmanos Cancer Institute Detroit, Michigan
Intervention DRUG: Dapagliflozin — 10mg orally once daily
Eligibility Ages 18 Years
Contact Christiane Houde · 3135768673 · Houdec@karmanos.org
L-THEANINE AND MEDITERRANEAN DIET ON RBD, GI FUNCTION, AND INFLAMMATION IN PARKINSON'S DISEASE
Medipol University n=52 Medipol Mega Hospital Istanbul
Intervention DIETARY_SUPPLEMENT: Dietary Supplement — L-theanine supplementation combined with Mediterranean diet for 4 weeks.
Eligibility Ages 50 Years – 80 Years
Contact Rüken A Samancı · +90 543 939 15 94 · rasamanci@medipol.edu.tr
Broccoli Sprout Extract for Cognitive Function
Pusan National University Yangsan Hospital n=100 Pusan National University Yangsan Hospital Yangsan
Intervention DIETARY_SUPPLEMENT: Broccoli sprout extract (BSE) — BSE 1,000 mg/day for 12 weeks
Eligibility Ages 50 Years – 85 Years
Contact Sang Yeoup Lee, Professor, MD, PhD · 360-2860 · drsaylee@gmail.com
Development of Digital Services for Parkinson's Disease
University of Exeter n=80 University of Exeter Exeter
Intervention DEVICE: gait with cueing wearable device and neuro-ocular performance — Participants will be invited to participate in the following sequential phases. Participants can participate in Phases a...
Eligibility Ages 18 Years
Contact Pavlos Evangelidis, PhD · 00447866138722 · p.evangelidis@exeter.ac.uk
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
University of California, Irvine n=50 University of California, Irvine Irvine, California
Eligibility Ages 18 Years
Contact Virginia Kimonis, MD · 949 824 0571 · vkimonis@uci.edu
An Online Physical Activity Coaching Intervention for People With PD in Qatar
Qatar University n=40 Qatar Rehabilitation Institution Doha
Intervention OTHER: 8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions — The first session will lay the groundwork for the program, in which an orientation of the features of the online forum w...
Eligibility Ages 18 Years
Contact Hanan Khalil prof Professor, phd · +974 30087097 · hkhalil@qu.edu.qa
Kimel Family Centre for Brain Health and Wellness
Baycrest n=450 Baycrest Toronto, Ontario
Intervention BEHAVIORAL: Physical Activity — Participants can chose (with input from a kinesiologist as required) from courses of varying intensity in our gym, warm ...
Eligibility Ages 50 Years
Contact Nicole D. Anderson, PhD, CPsych · 416-785-2500 · nanderson@research.baycrest.org
tDCS on Parkinson's Disease Cognition
University of Manitoba n=36 University of Manitoba Winnipeg, Manitoba
Intervention DEVICE: High-definition transcranial direct current stimulation — brain stimulation to increase neuronal excitability in the targeted regions
Eligibility Ages 40 Years
Contact Ji Hyun Ko, PhD · 204-318-2566 · ji.ko@umanitoba.ca
NCT07221838 PHASE4
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
Alexion Pharmaceuticals, Inc. n=75 Research Site Chicago, Illinois
Intervention PROCEDURE: Oral Corticosteroid Tapering Schedule — During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the partic...
Eligibility Ages 18 Years
Contact Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com